Clinical Trials in Salt Lake City

Showing 14161-14180 of 14,325 trials

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

NCT00147329

Merrimack is conducting a research study to see if an experimental drug, called MM-093, is safe and effective in the treatment of psoriasis. MM-093 is a genetically engineered version of a naturally occurring protein called alpha fetoprotein (AFP). Adults normally have very small amounts of AFP in their bloodstream. However, during pregnancy, AFP levels in both the mother and the fetus are much higher than normal. It has been observed that some women with psoriasis and other autoimmune diseases such as rheumatoid arthritis have fewer symptoms during pregnancy, particularly during the third trimester. At this time, the levels of AFP in the blood of the mother and fetus are the highest. This observation led Merrimack to begin examining MM-093 as a potential treatment for psoriasis. This study is designed to further test the safety and effectiveness of MM-093 in patients with psoriasis.

Psoriasis

Merrimack Pharmaceuticals30 participantsStarted Sep 2005

Dallas, Texas, United States • Salt Lake City, Utah, United States

COMPLETEDPhase 3< 1 mile

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

NCT00122304

The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH

Hemoglobinuria, Paroxysmal

Alexion Pharmaceuticals, Inc.85 participantsStarted Dec 2004

Los Angeles, California, United States • Stanford, California, United States • Hartford, Connecticut, United States +45 more locations

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

Find Trials by Condition in Salt Lake City

Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

ASSURE Study - Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICD Implantations

A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

APC-231 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) in Pediatric Patients With Strep Throat

Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause

Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.

Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients

Amonafide in Combination With Cytarabine in Secondary AML

Clinical Investigation of the SelectSecure Pacing Lead

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects

Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes

HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection

To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant

SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients

Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response